SEOUL, KOREA - Greencross Cellannounced on November 11 that it posted sales of 11.3 billion won and operatingprofit of 460 million won for the third quarter of this year on an IFRSbasis.Sales rose more than 60 percent compared to a year ago and operatingresults turned profitable.
Despite unstable globaleconomic conditions, the IT sales of its subsidiary Korea Hitech rose, whilethe sales of Immunecell-LC, an anti-cancer immune cell drug, rose sharply,clearing the way for Greencross Cell to remain profitable for two consecutivequarters starting from the second quarter of this year.
The number ofImmunecell-LC treatment cases shot up to 136 this year, up 184 percent fromlast year’s monthly average of 48.
The largest shareholderof Greencross Cell was changed to Green Cross in 2012 through a third-partycapital increase. Thereafter, Greencross Cell has been led by Han Sang-Heung, CEO of Green Cross Holdings.
Article provided by The Korea Economic Daily
